JPJiyang Pan

Jiyang Pan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiyang Pan has a total of 107 co-authors. Here are the top co-authors by number of shared publications:

  • Liwei Xie

    Institute of Microbiology, Guangdong Academy of Sciences

    4 shared publications
  • Xian Shi

    Department of Sleep Medicine Centre, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China; Department of Psychiatry, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China

    4 shared publications
  • Bingdong Liu

    Department of Psychiatry, The First Affiliated Hospital of Jinan University, Guangzhou, China

    3 shared publications
  • Guohuan Xu

    Department of Psychiatry, The First Affiliated Hospital of Jinan University, Guangzhou, China

    3 shared publications
  • Lutong Gan

    Sleep Medicine Center, The First Affiliated Hospital of Jinan University, Guangzhou, China

    3 shared publications
  • Shujie Chen

    Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China

    3 shared publications

Latest Publications

  • Increased presynaptic dopamine activity in adolescent with major depressive disorder: an 18F-FDOPA PET study

    by Xi-Zhe Sun, Yi-Xian Cai, Qi-Jun Cai, Xue-Ying Ling, Gui-Mei Zhang, Jing-Jing Lin, Ya-Xi Liu, Xian Shi, Tu-Zhi Wang, Biao Wu, et al.

  • Open Access

    Effects of CBT-I in modulating neuroplasticity in brain regions associated with insomnia disorder and serum 27-OHC levels

    by Xian Shi, Xiaoxuan Fan, Yixian Cai, Zhenye Luo, Yaxi Liu, Simeng Feng, Lutong Gan, Qi Wang, Liting Chen, Jiyang Pan

  • Open Access

    Population-Based Data Supporting Escitalopram as a Safer Antidepressant with Lower Mortality and Fewer Side Effects Compared to Other Medications

    by Zerui You, Tuzhi Wang, Lutong Gan, Simeng Feng, Jiyang Pan

    Purpose: This study aimed to compare the long-term safety profiles of different antidepressants. Methods: We utilized integrated databases, the National Health and Nutrition Examination Survey (NHANES) 2005-2018, to investigate the relationship between various antidepressants and health outcomes. Overall, 11 antidepressants were included in the main analysis, each used by at least 100 individuals with an average medication of over 40 months. Hazard ratios (HRs) and restricted mean survival time (RMST) were estimated to quantify differences in survival outcomes. Depression was assessed using the Patient Health Questionnaire-9. Results: A total of 5077 participants with depression were included. After adjustment, all antidepressants use had a trend toward increased long sleep duration risk (odds ratio [OR] range, 1.84-3.72; all p < 0.05) and reduced suicidal ideation risk (OR range, 0.25-0.47; all p < 0.05), except for mirtazapine. Users of bupropion, citalopram, duloxetine, sertraline, fluoxetine, and venlafaxine had higher obesity risk (OR range, 1.26-1.44; all p < 0.05). Only bupropion and escitalopram users were at lower risk for all-cause mortality, with an adjusted hazard ratio (aHR) of 0.66 (95% CI, 0.45 - 0.97; p = 0.036) for bupropion and 0.68 (95% CI, 0.47 - 0.93; p = 0.019) for escitalopram. Escitalopram users showed the most significant survival benefit (RMST difference, 30.1 [95% CI, 25.2-35.0] months; p < 0.001). Conclusions: Real-world evidence indicates that antidepressants have an extensive impact on overall health. Escitalopram is linked to reduced all-cause mortality risk and improved survival outcomes, suggesting its potential as a better treatment option for depression.

  • Open Access

    Distinct Gut Microbiota Profiles Reflect Severity in Chronic Insomnia Disorder

    by Yaxi Liu, Yixian Cai, Xian Shi, Mei Fan, Xiaotao Zhang, Jingjing Lin, Xiaoxuan Fan, Bingdong Liu, Jiyang Pan

    Introduction: Severe insomnia symptoms increase the risk of persistent sleep disorders, underscoring the need for timely identification to optimize therapeutic interventions. Given the established association between chronic insomnia disorder (CID) and gut microbiota, this study aimed to evaluate the utility of gut microbiota characteristics for stratifying CID severity. Methods: A total of 65 patients with CID were categorized into two groups based on Pittsburgh Sleep Quality Index (PSQI) scores: S‐CID (more severe poor sleep quality; median age: 36, IQR: 30–47; M/F: 12/22) and M‐CID (milder poor sleep quality; median age: 33, IQR: 25–43; M/F: 11/20). Thirty healthy controls (HC; median age: 32, IQR: 26–48; M/F: 8/22) were also included. All participants underwent polysomnography and clinical assessments. Fecal samples were collected and analyzed via 16S rRNA gene sequencing. We compared microbial structure across severity groups, identified key bacterial genera using LASSO regression and the Boruta algorithm, and examined their correlations with sleep parameters via Spearman analysis. Functional pathway predictions were performed with PICRUSt2. A random forest model was constructed to evaluate severity‐stratified discriminative capacity. Results: Significant alterations in gut microbial diversity and composition were observed in S‐CID patients compared to HC, whereas M‐CID patients showed less pronounced differences. Seven key bacterial genera were identified and consistently correlated with sleep parameters. Functional perturbations in glutamate/butanoate metabolism and branched‐chain amino acid degradation pathways differed by severity. The random forest model demonstrated moderate efficacy (AUC = 0.711–0.730) in distinguishing S‐CID patients based on microbial signatures. Conclusion: This study reveals distinct gut microbial signatures associated with varying severity levels of CID, providing insights that may support the development of microbiota‐based diagnostic and therapeutic interventions.


  • Open Access

    Relationship between antidepressants with side effects and mortality in adults with depressive symptoms: evidence from a large population-based study

    by Zerui You, Tuzhi Wang, Lutong Gan, Simeng Feng, Jiyang Pan

    Aims: This study aims to assess the side effects and mortality risks of different antidepressants. Methods: We utilized integrated databases, the National Health and Nutrition Examination Survey (NHANES) 2005-2018, to investigate the relationship between various antidepressants and health outcomes. Overall, 11 antidepressants were included in the main analysis, each used by at least 100 individuals with an average medication of over 40 months. Hazard ratios (HRs) and restricted mean survival time (RMST) were estimated to quantify differences in survival outcomes. Depression was assessed using the Patient Health Questionnaire-9. Results: A total of 5077 participants with depression were included. After adjustment, all antidepressants use had a trend toward increased long sleep duration risk (odds ratio [OR] range, 1.84-3.72; all p < 0.05) and reduced suicidal ideation risk (OR range, 0.25-0.47; all p < 0.05), except for mirtazapine. Users of bupropion, citalopram, duloxetine, sertraline, fluoxetine, and venlafaxine had higher obesity risk (OR range, 1.26-1.44; all p < 0.05). Only bupropion and escitalopram users were at lower risk for all-cause mortality, with an adjusted hazard ratio (aHR) of 0.66 (95% CI, 0.45 - 0.97; p = 0.036) for bupropion and 0.68 (95% CI, 0.47 - 0.93; p = 0.019) for escitalopram. Escitalopram users showed the most significant survival benefit (RMST difference, 30.1 [95% CI, 25.2-35.0] months; p < 0.001). Conclusions: Real-world evidence indicates that antidepressants have an extensive impact on overall health. Escitalopram is linked to reduced mortality risk and improved survival outcomes, suggesting its potential as a better treatment option for depression.

  • Open Access

    Neuroendocrine abnormalities as predictors of suicidal ideation in bipolar disorder patients during depressive episodes: a cross-sectional study

    by Xiaoxuan Fan, Xian Shi, Fangyi Deng, Yixian Cai, Yaxi Liu, Yang Zhao, Heng Wang, Jiwu Liao, Jiyang Pan

    Bipolar disorder (BD) is a psychiatric disorder with a high prevalence of suicidal ideation (SI). While the relationship between BD and the endocrine system is well established, the influence of neuroendocrine hormones on SI during depressive episodes remains poorly understood. This cross-sectional study aimed to identify high-risk neuroendocrine factors for SI and evaluate their predictive efficacy using machine learning techniques. Data were obtained from the electronic medical records of patients hospitalized for BD depressive episodes at The First Affiliated Hospital of Jinan University in Guangzhou, Guangdong Province, China between January 1, 2017, and October 31, 2022. Of 635 eligible patients, 380 exhibited SI. In the multivariate analysis, lower levels of FT4 (OR = 0.925; 95% CI = 0.869–0.986; P = 0.017) and testosterone (OR = 0.799; 95% CI = 0.642–0.993; P = 0.043) were significantly associated with an increased risk of SI. Additionally, an earlier age of onset (OR = 0.936; 95% CI = 0.897–0.977; P = 0.002) and the presence of psychotic symptoms contributed to a higher risk of SI. Furthermore, we developed a supervised learning model—Naive Bayes classifier. The model identified age of onset as a key predictor of SI during depressive episodes of BD, highlighting its importance as the most relevant predictive variable for distinguishing patients at risk of SI. These findings could help clinicians more accurately identify BD patients with higher suicide risk, thereby improving diagnostic sensitivity for this disorder.


  • Open Access

    Benefits and risks of sleep medication in individuals with hypertension and sleep disturbance: evidence from a large population-based study

    by Zerui You, Duan Liu, Tuzhi Wang, Heng Wang, Jiyang Pan

    The benefits and risks of sleep medications among patients with hypertension and sleep disturbance remain unclear. This study aims to investigate the potential benefits and risks of sleep medications in this population. This was a prospective cohort study among US adults, using hypertension and medication data from the National Health and Nutrition Examination Survey (NHANES). Linear regression assessed the efficacy of sleep medications in controlling blood pressure. Cox regression explored associations between sleep medications and mortality. This study included 4836 participants taking antihypertensive medication with sleep disturbance. Compared with non-users, benzodiazepine users had an adjusted estimated systolic blood pressure (SBP) difference of -2.22 mmHg (95% CI, -3.70 to -0.74; P = 0.003), while benzodiazepine-like agents (Z-drugs) users had a more pronounced difference of -3.33 mmHg (95% CI, -5.85 to -0.81; P = 0.010), with diazepam, clonazepam, and zolpidem demonstrating significant antihypertensive effects. The median follow-up time was 82.3 months, and 809 all-cause deaths occurred. Sleep medications (hazard ratio [HR]: 1.14; 95% CI, 0.97 to 1.33; P = 0.120) and benzodiazepine users (HR: 1.05; 95% CI, 0.87 to 1.26; P = 0.639) were not associated with an increased risk of all-cause mortality, while Z-drug users were linked to a higher risk (HR: 1.39; 95% CI, 1.04 to 1.85; P = 0.025) compared to non-users. No significant association was found with cardiovascular mortality. Sleep medication use is associated with lower blood pressure and is not significantly associated with an elevated mortality risk among hypertensive participants with sleep disturbance.


  • Open Access

    The Abnormal N-Acetylaspartate to Creatine Ratio of the Right Putamen is Linked to Wakefulness in Patients with Insomnia Disorder

    by Qiaoting Huang, Changzheng Shi, Saurabh Sonkusare, Congrui Li, Valerie Voon, Jiyang Pan

    Purpose: Converging evidence implicates the putamen in sleep-wake regulation. However, its role remains unclear. We hypothesized that metabolic abnormalities in the putamen are linked to insomnia disorder, which has not been previously addressed, and investigated putaminal N-acetylaspartate (NAA), choline (Cho), and creatine (Cr) in patients with insomnia disorder compared to healthy controls. Participants and Methods: In the present study, the concentrations of NAA, Cho, and Cr in the putamen of 23 patients with insomnia disorder and 18 healthy controls were determined using proton magnetic resonance spectroscopy. Sociodemographic, psychometric, and polysomnography data were obtained from all participants. Results: We found that the mean NAA/Cr ratio of the right putamen was significantly greater in the insomnia group compared to the control group and also greater than the left putamen within the insomnia group. The NAA/Cr ratio of the right putamen distinguished insomnia disorder from normal sleep with 78.3% sensitivity and 61.1% specificity. Furthermore, this ratio positively correlated with both objective and subjective insomnia severity and sleep quality. Conclusion: Our findings provide critical evidence for the dysfunctional putaminal metabolism of NAA/Cr in insomnia disorder, suggesting that the abnormal NAA/Cr ratio of the right putamen is linked to wakefulness in patients with insomnia disorder and may serve as a potential biomarker of insomnia disorder.


  • Open Access

    Markers of intestinal barrier damage in patients with chronic insomnia disorder

    by Yixian Cai, Di Gong, Ting Xiang, Xiaotao Zhang, Jiyang Pan

    Objective: Insomnia disorder stands out as one of the prevalent clinical sleep and psychiatric disorders. Prior research has unequivocally demonstrated variations in the diversity and abundance of gut microbiota among individuals with insomnia disorder. These alterations may play a direct or indirect role in the onset and progression of insomnia disorder by compromising the integrity of the intestinal barrier. This study aims to evaluate the impairment of the intestinal barrier in individuals with insomnia disorder by scrutinizing the serum functionality of this barrier.Materials and methods: 45 patients with chronic insomnia disorder and 30 matched healthy volunteers were meticulously selected based on inclusion criteria. ELISA technology was employed to measure serum levels of diamine oxidase (DAO), D-lactic acid (D-LA), intestinal fatty acid binding protein (I-FABP), and endothelin (ET). Spearman correlation analysis was used to explore the relationship between intestinal mucosal markers and clinical characteristics. Data were analyzed using SPSS 26.0.Results: Compared to the healthy control group, the insomnia disorder group exhibited significantly elevated scores on subjective mood and sleep scales (GAD-7, PHQ-9, HAMA, HAMD, PSQI, and ISI) (P < 0.05). Overnight PSG indicated a notable increase in bed time, total wake time, sleep onset latency, and wake after sleep onset in individuals with insomnia disorder. Additionally, there was a decrease in sleep efficiency and alterations in sleep structure (increased proportion of N1 and N3 stages, prolonged N1 stage) (P < 0.05). The chronic insomnia disorder group displayed significantly reduced concentrations of serum DAO, D-LA, I-FABP, and ET (P < 0.05). Furthermore, significant positive correlations were identified between intestinal epithelial barrier markers and sleep efficiency, while negative correlations were found with wake after sleep onset, total wake time, PSQI, HAMA, and HAMD. Additionally, D-LA levels were significantly positively correlated with ET concentrations.Conclusion: Individuals with chronic insomnia disorder manifest disruptions in sleep structure, heightened susceptibility to anxiety and depressive moods, and impaired intestinal barrier function. These findings suggest that the occurrence and development of insomnia disorder may be linked to the impairment of the intestinal barrier.


  • Open Access

    Negative perfectionism and sleep quality in Chinese international students under COVID-19 epidemic: A moderated mediation

    by Huang Zhaoyang, Chen Feng, Fan Mei, Lin Jingjing, Pan Jiyang

    Objective: This study used a moderated mediation model to test the mediating effect of anxiety on the relationship between negative perfectionism and sleep quality and the moderating effect of COVID-19 epidemic risk perception during the COVID-19 pandemic in Chinese international students.Materials and methods: A sample of 239 Chinese international students from the south of China, was surveyed with the Negative and Positive Perfectionism Scale, the Pittsburgh Sleep Quality Index, the General Anxiety Disorder Scale, and the COVID-19 Epidemic Risk Perception Inventory. Version 23.0 of SPSS and version 3.4 of PROCESS were used to perform the correlation analyses, mediation analysis, and moderated mediation analysis.Results: (1) Negative perfectionism was significantly correlated with anxiety (r = 0.371, p < 0.01) and poor sleep quality (r = 0.291, p < 0.01). Anxiety was significantly correlated with poor sleep quality (r = 0.594, p < 0.01). (2) The mediating effect test showed that anxiety had a mediating effect between negative perfectionism and poor sleep quality (β = 0.157, p < 0.01). (3) Epidemic risk perception moderated the mediating effect of anxiety between negative perfectionism and poor sleep quality (β = 0.070, p < 0.01).Conclusion: Negative perfectionism affected sleep quality indirectly through anxiety. In particular, COVID-19 epidemic risk perception moderated the relationship between anxiety and sleep quality, such that the association was stronger when the COVID-19 epidemic risk perception was high. These results provide a more comprehensive understanding of the negative link between negative perfectionism and poor sleep quality.